Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 7/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1638298 | 0.88 | CXCR4 (0.45) | KCNA5CXCR4HDAC3HDAC1HDAC2 | |
| SCHEMBL1638167 | 0.84 | CXCR4 (0.47) | KCNA5CXCR4HDAC3HDAC1HDAC2 | |
| SCHEMBL1638534 | 0.82 | CXCR4 (0.45) | KCNA5CXCR4HDAC3HDAC1HDAC2 | |
| SCHEMBL1637497 | 0.81 | CXCR4 (0.50) | KCNA5CXCR4HDAC3HDAC1HDAC2 | |
| SCHEMBL1638369 | 0.79 | CXCR4 (0.68) | KCNA5TSHRCNR2CXCR4MAPT | |
| SCHEMBL1637307 | 0.76 | CXCR4 (0.68) | CXCR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL1638209 | 0.76 | CNR2 (0.42) | CNR2TAS2R14POLBF2 | |
| SCHEMBL1636495 | 0.75 | HDAC3 (0.40) | KCNA5TSHRCXCR4POLBHDAC3 | |
| SCHEMBL1206671 | 0.74 | L3MBTL1 (0.40) | CXCR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL1204948 | 0.72 | HDAC3 (0.39) | CXCR4HDAC3HDAC1HDAC2NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1724263-B1 | BASIC AMINE COMPOUND AND USE THEREOF | KUREHA CORP (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | KUREHA CORPORATION (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932281-B2 | Amine-based compound and use thereof | KUREHA CORPORATION (JP) | 2011-04-26 | — | — | US | disclosed |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | KUREHA CORPORATION (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1724263-A1 | BASIC AMINE COMPOUND AND USE THEREOF | Kureha Corporation (JP) | 2006-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172212-A1 | AMINE-BASED COMPOUND AND USE THEREOF | NR0B2, NR5A2, NR1D2 | KCNA5 1359/4885TSHR 1111/4885CNR2 274/4885 |
| US-20070208007-A1 | Amine-Based Compound and Use Thereof | NR0B2, NR5A2, NR2E1 | KCNA5 1575/4885TSHR 1353/4885CNR2 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.